Myomo, Inc. (MYO)
| Market Cap | 12.68M |
| Revenue (ttm) | 15.56M |
| Net Income (ttm) | -10.72M |
| Shares Out | 20.92M |
| EPS (ttm) | -1.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 419,172 |
| Open | 0.600 |
| Previous Close | 0.600 |
| Day's Range | 0.589 - 0.624 |
| 52-Week Range | 0.369 - 4.530 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 5.13 (+746.26%) |
| Earnings Date | Mar 13, 2023 |
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cor... [Read more]
Financial Performance
In 2022, Myomo's revenue was $15.56 million, an increase of 12.26% compared to the previous year's $13.86 million. Losses were -$10.72 million, -2.64% less than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MYO stock is "Buy." The 12-month stock price forecast is $5.13, which is an increase of 746.26% from the latest price.
News
Myomo Makes NYSE American Section 610(b) Public Announcement
BOSTON--(BUSINESS WIRE)--Myomo, Inc.
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 34.09% and 0.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo Reports Fourth Quarter and Full Year 2022 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Report Fourth Quarter Financial Results on March 13, 2023
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Report Third Quarter Financial Results on March 13, 2023
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo To Participate in the 35th Annual Roth Conference
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
MyoPro Approved in Australia by National Disability Insurance Scheme
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
7 Top Short-Squeeze Candidates to Watch in February
While everyone knows that in order to have a market, there must be bulls and bears, that's not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quic...
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological di...
Myomo Announces Closing of $6.5 Million Upsized Public Offering
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological di...
Myomo Announces Pricing of $6.5 Million Upsized Public Offering
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological di...
Myomo Announces Initiative to Reduce Cash Burn
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological di...
Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological di...
Ruling by German Social Court Supports MyoPro Reimbursement by Nation's Statutory Health Insurance System
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological di...
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological di...
Myomo to Report Third Quarter Financial Results on November 10, 2022
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo To Present at the MicroCap Rodeo Presents The Windy City Roundup 2022
BOSTON, MA / ACCESSWIRE / October 5, 2022 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from...
Myomo to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 6.67% and 4.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
Myomo to Report Second Quarter Financial Results on August 3, 2022
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...
What Makes Myomo, Inc. (MYO) a New Strong Buy Stock
Myomo, Inc. (MYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological diso...